Topics

Bristol-Myers Squibb and Pfizer Company Profile

05:39 EDT 20th September 2019 | BioPortfolio

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.


News Articles [1868 Associated News Articles listed on BioPortfolio]

Bristol-Myers and Squibb-Pfizer report positive AUGUSTUS trial data

The Bristol-Myers Squibb-Pfizer Alliance has reported positive results from the Phase IV AUGUSTUS trial that evaluated Eliquis (apixaban) versus vitamin...Read More... The post Bristol-Myers and Squib...

Bristol-Myers Squibb Pulls 3 Programs out of CytomX Partnership

Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional target...

Bristol-Myers and Pfizer report positive AUGUSTUS trial data

The Bristol-Myers Squibb-Pfizer Alliance has reported positive results from the Phase IV AUGUSTUS trial that evaluated Eliquis (apixaban) versus vitamin...Read More... The post Bristol-Myers and Pfize...

Deep Dive: Bristol-Myers Squibb's Celgene Acquisition

Bristol-Myers Squibb and Celgene Corporation are strongly urging shareholders to submit their proxy votes as quickly as possible whether they plan to attend the April 12, 2019 Special Meeting or not. ...

Starboard Value Opposes Bristol-Myers Squibb's Acquisition Of Celgene

SUMMIT (dpa-AFX) - Starboard Value LP, a stockholder of Bristol-Myers Squibb Company (BMY), said that it has delivered an open letter to Bristol-Myers stockholders expressing its belief that the p...

Catalent to Buy Bristol-Myers' Factory in Italy, Adding to Latest String of Expansions

The facility has acted as one of Bristol-Myers Squibb’s primary launch facilities for new drugs. After the deal is closed, Catalent will continue to manufacture Bristol-Myers Squibb’s current prod...

Bristol-Myers Squibb Strikes Back! Responds to Critics of Celgene Deal

Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholde...

Bristol-Myers Squibb Strikes Back! Response to Critics of Celgene Deal

Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholde...

Drugs and Medications [121 Associated Drugs and Medications listed on BioPortfolio]

Entecavir [accord healthcare inc.]

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets, for oral use Ini...

Entecavir [golden state medical supply inc.]

ENTECAVIR TABLETS These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets...

Vyndaqel [pfizer labs division of pfizer inc.]

Vyndaqel

Entecavir [avkare, inc.]

Entecavir Tablets These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS. ENTECAVIR tablets,...

Entecavir [par pharmaceutical, inc.]

These highlights do not include all the information needed to use Entecavir Tablets safely and effectively. See full prescribing information for Entecavir Tablets.Entecavir tablets, for oral useInitia...

PubMed Articles [164 Associated PubMed Articles listed on BioPortfolio]

Storm warning: lung disease in systemic juvenile idiopathic arthritis.

Dr. Nigrovic's work was supported by the NIH grants R01 AR065538, AR075906, AR073201 and P30 AR070253, the Fundación Bechara and the Arbuckle Family Fund for Arthritis Research. PAN is the recipient ...

AMCP Partnership Forum: Integrated Delivery Networks' Role in Pharmaceutical Value-Based Agreements.

Health care payment models that reward value over volume have the potential to improve patient care and control rising costs. These payment models are increasingly being implemented by a range of care...

A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study.

Anticoagulation in children is problematic for multiple reasons. Currently used anticoagulants have significant disadvantages and may negatively affect quality of life (QOL). This manuscript describes...

LAG-3 antagonists by cancer treatment: a patent review.

: LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused...

John King, the Bristol surgeon and friend of artists and poets.

The Bristol School of Artists developed between 1800 and 1840 and was a collaboration between professional and amateur artists, one of whom was Dr John King. King started his professional life in Bris...

Clinical Trials [175 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Companies [229 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb-Pfizer Alliance

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

More Information about "Bristol-Myers Squibb and Pfizer" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb and Pfizer news stories on BioPortfolio along with dozens of Bristol-Myers Squibb and Pfizer Clinical Trials and PubMed Articles about Bristol-Myers Squibb and Pfizer for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb and Pfizer Companies in our database. You can also find out about relevant Bristol-Myers Squibb and Pfizer Drugs and Medications on this site too.

Quick Search

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record